Safety of Inpatient Dofetilide Initiation per Cardiology Services: A Retrospective Review | Zendy

Carrie Cicirale | Zendy; Jennifer Jackson | Zendy; David Gothard | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety of Inpatient Dofetilide Initiation per Cardiology Services: A Retrospective Review

Author(s) -

Carrie Cicirale,

Jennifer Jackson,

David Gothard

Publication year - 2021

Publication title -

journal of pharmacy practice

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.407

H-Index - 28

eISSN - 1531-1937

pISSN - 0897-1900

DOI - 10.1177/08971900211000212

Subject(s) - dofetilide , medicine , retrospective cohort study , incidence (geometry) , adverse effect , atrial fibrillation , cardiology , sudden cardiac death , emergency medicine , anesthesia , physics , optics

Dofetilide is an antiarrhythmic medication that has the potential to cause life threatening arrhythmias, such as Torsade de pointes. The 2014 ACC/AHA/HRS guidelines for the management of patients with atrial fibrillation state that patients need to meet certain criteria to be initiated on dofetilide. Patients who are not initiated on this therapy according to the guideline criteria are likely to be at higher risk of adverse reactions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research